Document is current
Any future updates will be listed below
-
Authors
Andersen, Lærke Sloth https://orcid.org/0009-0001-6878-8602
Mæng, Cecilie Velsø https://orcid.org/0000-0002-7205-9330
Rögnvaldsson, Sæmundur https://orcid.org/0000-0003-2162-8414
Long, Thórir Einarsson https://orcid.org/0000-0003-2377-7886
Brieghel, Christian https://orcid.org/0000-0002-1816-8106
Hermansen, Emil https://orcid.org/0000-0002-1754-5336
Andersen, Morten Nørgaard
Grønbæk, Kirsten https://orcid.org/0000-0002-1535-9601
Niemann, Carsten Utoft https://orcid.org/0000-0001-9880-5242
Kristinsson, Sigurður Yngvi https://orcid.org/0000-0002-4964-7476
Thorsteinsdóttir, Sigrún https://orcid.org/0000-0001-5017-3530
- License Information
-
More Information
Article History
Received: 6 November 2025
Revised: 13 February 2026
Accepted: 12 March 2026
First Online: 30 March 2026
Competing interests
: LSA has participated in a conference supported by Alexion. CVM has participated in a conference supported by Daiichi Sankyo. SR reports honoraria for scientific talks from Johnson & Johnson and Siemens Healthineers. CB has received travel grants from AbbVie and AstraZeneca. EH reports honoraria for lectures and educational materials from Amgen, Bristol Myers Squibb, Johnson & Johnson, Pfizer, Sanofi, and Takeda, research cooperation with Bristol Myers Squibb, Johnson & Johnson, and Sanofi, participation in conferences supported by Bristol Myers Squibb, Pfizer, Roche, and Takeda, and advisory board consultancy to Johnson & Johnson, Sanofi, and Oncopeptides. CUN has received research funding from AbbVie, Johnson & Johnson, AstraZeneca, Genmab, and Octapharma, and has provided consultancy for AbbVie, BeiGene, Janssen, Roche, AstraZeneca, CSL Behring, Genmab, Takeda, Octapharma, MSD, Synamics, and Lilly. KG has received research funding from Janssen and Medac. SYK reports research funding from Amgen and Celgene; Independent Data Monitoring Committee for Jansen. ST reports honoraria for scientific talks for Abbvie, GlaxoSmithKline and Thermo Fisher Scientific, advisory board for Sanofi, travel grant from Amgen and conference participation supported by GlaxoSmithKline. The remaining authors declare no competing interests.
: The study was conducted under the approval of Danish Lymphoid Cancer Research (DALYCARE) protocol by the Danish National Ethics Committee (1804410) and Data Protection Agency (P-2020-561).
